Amanote Research
Register
Sign In
The Majority of AML Mutations Are Preexisting Passenger Events
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2012-116
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
August 2, 2012
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
MED12 Mutations Are Present in the Majority of Uterine Leiomyomas
Cancer Discovery
Oncology
Heterogeneity Within AML With CEBPA Mutations; Only CEBPA Double Mutations, but Not Single CEBPA Mutations Are Associated With Favourable Prognosis
British Journal of Cancer
Cancer Research
Oncology
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
American Journal of Pathology
Forensic Medicine
Pathology
Using Passenger Mutations to Estimate the Timing of Driver Mutations and Identify Mutator Alterations
BMC Bioinformatics
Biochemistry
Applied Mathematics
Computer Science Applications
Structural Biology
Molecular Biology
Validated Bayesian Differentiation of Causative and Passenger Mutations
G3: Genes, Genomes, Genetics
Medicine
Genetics
Molecular Biology
Dominating the Negative: How DNMT3A Mutations Contribute to AML Pathogenesis
Cell Stem Cell
Molecular Medicine
Genetics
Cell Biology
Preexisting Oncogenic Events Impact Trastuzumab Sensitivity in ERBB2-amplified Gastroesophageal Adenocarcinoma
Journal of Clinical Investigation
Medicine
Somatic USP8 Mutations Are Frequent Events in Corticotroph Tumor Progression Causing Nelson’s Tumor
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes
Donor HSCs With a Preexisting ASXL1-mutation Led to the Development of FLT3-ITD Positive AML in the Donor and FLT3-ITD Negative AML in the Recipient After Unrelated Transplant
Bone Marrow Transplantation
Transplantation
Hematology
